AEON Biopharma Inc Sustainability Reports
A clinical-stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450, for the treatment of multiple debilitating medical conditions.
Sector: Manufacturing
Country: United States
Exchange: NYSE American
6 reports from 2020 to 2025